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Anti-lymphocyte antibodies (ALA) are used extensively in organ transplantation as 
immunosuppressive agents. These antibodies may be of non-human species, human, 
humanized, chimeric, or a combination of these.  Rituximab, sold as Rituxan
TM
, is a 
humanized chimeric monoclonal antibody that is approximately 25% murine (anti-CD20 
antibody 2B8) and 75% human antibody. Specifically, the Fc portion of rituximab is 
human IgG1 that can bind to human complement and initiate antibody dependent cellular 
cytotoxicity (ADCC) as well as complement dependent cytotoxicity (CDC). Rituximab 
was initially developed to treat B cell lymphoma via its ability to bind to the CD20 
molecule on B cells. Several different mechanisms of action have been proposed and, in 
all, the end result is B cell depletion, both neoplastic and normal. Recently, rituximab has 
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been included as part of pre-transplant conditioning regimens among allosensitized 
patients awaiting renal transplantation. Post-transplant, rituximab has been used to 
prevent and/or treat allograft rejection (both acute and chronic) and to facilitate ABO 
mismatched kidney transplants (1). When used in these clinical situations, the presence of 
rituximab in patient sera may interfere with transplant immunologic monitoring. 
 
Preformed alloantibodies (predominantly HLA specific) in a sensitized individual react 
with antigens expressed on the vascular endothelial cells of organ allografts. Such 
antibodies can activate the classical complement pathway resulting in rapid necrosis of 
the transplanted tissue.  Prior sensitization of recipients to donor alloantigens occurs by 
pathways including blood transfusion, pregnancies and previous allografts. The 
performance of a crossmatch immediately before the transplant is still performed as a 
measure to prevent hyperacute or accelerated allograft rejection. As well, crossmatch 
monitoring may be performed after transplant. Thus, the persistence of rituximab in 
patient serum/plasma can negatively impact crossmatch and alloantibody analysis. Since 
rituximab is cytotoxic in the presence of complement, sera that contain rituximab may 
result in a positive cytotoxic crossmatch assay, a result that would be mistakenly 
attributed to donor directed HLA alloantibodies.  Additionally, the human portion of the 
chimeric monoclonal antibody provides a target for the anti-human Ig fluorochromes, 
thereby resulting in a positive flow cytometric crossmatch. Clearly, it is challenging to 
perform transplant crossmatch analysis when exogenous anti-lymphocyte antibodies such 
as rituximab are present. To overcome this issue, several methods can be applied.  One 
method uses pronase, a proteolytic enzyme that removes CD20 from the surface of B 
cells by Fc receptor digestion (CD20 is a member of the Fc receptor family of proteins) 
(2). After CD20 is removed, rituximab typically no longer binds B cells, thereby making 
it possible to clearly detect class I and II Major Histocompatibility (MHC) antibodies 
using B cell targets.  An alternative to Fc receptor digestion is to adsorb rituximab from 
the serum onto microparticles coated with polyclonal anti-mouse antibody (3).   
 
Herein, we modify the conjugated bead assay described above.  Instead of an anti-mouse 
antibody, a small fragment of the extracellular CD20 structure (residues 163 – 187) that 
  
specifically binds rituximab is conjugated to a microparticle suspension.  Conjugating the 
CD20 peptide to biotin facilitates removal of rituximab, thereby permitting binding to 
streptavidin-conjugated magnetic particles.   
 
Methods and Materials: 
Peptide preparation: 
Peptide was prepared at the Peptide Core Facility, Indiana University School of Medicine, 
Indianapolis, IN. 
The synthesis of cyclic peptide [NIYNCEPANPSEKNSPSTQYCYSIQ-K(PEG2-Biotin)-
G, with S-S bond] was started on Fmoc-Gly-Wang resin (Midwest Bio-tech, Fishers, IN) 
using Fmoc chemistry. After the Lys(Mtt)
26
 was coupled, the peptide-resin bearing the 
Mtt-protected lysine was treated with TFA/TIS/DCM (1:5:94) to remove Mtt group. The 
N-Biotinyl-NH-(PEG)2-COOH.DIPEA (Nova Biochem, Billerica, MA) was conjugated 
to the ε-amino group of lysine. The continuing synthesis of the peptide was carried out 
on an ABI 433A peptide synthesizer (Applied Biosystems Inc. Foster City, CA), using 
Fmoc chemistry and trityl-protected Cys.  The cleavage of the peptide from resin and 
side-chain protecting group removal was accomplished using trifluoroacetic acid id cocktail 
solution and the crude peptide was precipitated with ether and lyophilized. The disulfide 
bond formation of the peptide was carried out in 10% of dimethyl sulfloxide in phosphate 
buffered saline (PBS) at pH 7.4. The final peptide was purified by C18 preparative 
reverse-phase HPLC and was characterized by analytical HPLC and molecular weight 
analysis using mass spectrometer.  
 
Conjugation to Beads: 
The purified peptide was reconstituted with 0.1% bovine serum albumen (BSA). Twenty-
five nMoles of solubilized peptide were added to 16.75 X 10
6 
washed Dynal M-280 
super-paramagnetic polystyrene beads (Invitrogen, Carlsbad, CA). The peptide and 
beads, precoated with streptavidin covalently attached to the hydrophobic surface, were 
incubated for 30 minutes at room temperature in a 12 X 75 polystyrene tube. No 
difference in absorption was noted with twice or half as much peptide for the same 
amount of beads, or when the incubation time was changed in time intervals ranging from 
  
15, 30, 40, 60, 75 minutes to 4 hours. Excess peptide solution was removed by adhering 
the beads to a magnet for 3 minutes and discarding the supernatant. This step was 
repeated three times. The peptide-coated beads could then be stored in the refrigerator at 
4
o
C until ready to use. 
 
Adsorption of rituximab from serum: 
One hundred µL of the bead suspension were added to a 12 X 75 polystyrene tube. The 
peptide-coated beads were resuspended in 2.5 mL of BSA solution then adhered to a 
magnet for 3 minutes before decanting eliminated the supernatant. Normal human serum 
(NHS) containing rituximab or appropriate controls were then added to the beads and 
incubated for 15 minutes on a rocker at room temperature. The beads were removed by 
adherence to a magnet for 3 minutes. The serum was retained and further adsorbed as 
needed by repeating the above steps until no presence of rituximab was noted. The final 
adsorbed serum was now available for routine crossmatching techniques such as flow 
cytometry, or cytotoxicity assays. 
 
Flow cytometric crossmatch: 
Donor mononuclear cells were isolated by density gradient centrifugation. 250,000 
isolated cells were incubated with purified anti-CD20 antibody (Becton Dickinson, San 
Jose, CA) for 10 minutes followed by 25 µL of test (adsorbed) serum with incubation on 
ice. The cells were washed with BSA solution containing sodium azide. Binding of 
human IgG was detected with fluoresceinated (FITC) goat F(ab)2 anti-human IgG 
antibody (Jackson ImmunoResearch, West Grove, PA). The presence of CD19 or CD20 
was detected with antibodies coupled to phycoerythrin (PE) (Becton Dickinson, San Jose, 
CA). Samples were analyzed by an Epics XL flow cytometer. Results are expressed as 
median fluorescence values (MFI) for green fluorescence (FITC) and red fluorescence 
(PE) and percent of positive cells. 
 
Results: 
A representative experiment is shown in figures 1 and 2. MFI of log green and red 
fluorescence and percent positive cells was compared for sera before and after treatment 
  
and with or without rituximab. MFI green fluorescence was 0.280 for NHS, 4.44 for NHS 
containing 10  µg/mL of rituximab before adsorption and 1.32 after 5 treatments. This 
indicated that less interfering rituximab was bound to the CD20 surface antigen expressed 
on B cells identified by binding of the goat anti-human IgG F(ab’)2 FITC conjugated 
antibody.  Further analysis showed that percent positive PE fluorescence measuring 
directly conjugated anti-human CD20 PE binding to the cells was 56.7 in NHS without 
rituximab, 0.84 for NHS containing 10 µg/mL of rituximab before adsorption, and 56.7 
after 5 adsorptions. MFI of PE-conjugated anti-human CD20PE was 32.9 for NHS 
without rituximab, 0.903 for NHS containing 10 µg /mL of rituximab before adsorption, 
and 18.6 after 5 treatments. This indicated that rituximab interference had been reduced. 
Alloantibody binding was not affected by adsorption. With a pooled HLA-positive sera 
MFI for green fluorescence was 4.83 before and 4.11 after 5 treatments. No change was 
seen in CD19 with binding MFI red fluorescence was 4.26 (75.2%+) before and 4.53 
(76.2%+) after 5 treatments. Complement dependent cytotoxicity (CDC) testing using 
these sera and cells from the same donor showed negative results for both T cell and B 
cell crossmatches for NHS, and NHS containing 10 µg/mL of rituximab after 5 
treatments. B cell crossmatches were positive by CDC with NHS containing 10 µg/mL of 
rituximab and positive control. T cell crossmatches were positive for only positive 
control and negative for NHS containing 10 µg/mL of rituximab. 
 
Discussion: 
 
In the United States, the number of highly sensitized patients awaiting renal transplant 
have continued to rise with more 100,000 patients awaiting transplantation in 2014. with 
14% having panel reactive antibody >80%. (5). Whether a patient has HLA antibodies to 
a given donor is commonly determined by a combination of solid phase detection assays 
and cell based crossmatch testing in the histocompatibility laboratory. Pretransaplant 
presence of HLA donor specific antibodies (DSA) is typically a contraindication for 
kidney transplantation. It has been previously shown that rituximab interferes with cell 
based crossmatch techniques such as the CDC assay and flow cytometric B cell 
crossmatching.  Levels of rituximab have been shown to be present at 6 months with a 
single dose of 375/m
2
. (6.) Several methods have been described to remove rituximab 
  
from patient sera.  The method we currently describe is an effective and more efficient 
way to remove rituximab from sera/plasma by allowing CD20 antigen beads to be 
prepared in bulk, validated and stored until required for use. There in minimal additional 
time required at the time of clinical testing whether before or after transplantation.   This 
would facilitate the crossmatch testing of those patients who had received rituximab for 
clinical indications. 
 
Pronase is proteolytic enzyme used frequently in histocompatibility laboratories at low 
doses to remove fc-like receptors from the cell surface of donor cells. While high doses 
of pronase effectively cleaves the CD20 that is also in the Fc receptor super family, from 
the surface of B cells, it is a harsh treatment. A number of cells are lost during this 
treatment. Loss of scarce donor cells could be a problem when crossmatching multiple 
donors or in post-transplant monitoring. As well, some investigators have shown that 
pronase may be inadequate for preparing cells for crossmatching with patients receiving 
rituximab  (7). 
 
Removing the interfering rituximab from the serum is another effective approach to this 
problem. However, there are currently no commercially available reagents that address 
this issue.  While effective, the method described in Bearden et al. (3) requires multiple 
steps and may be considered impractical in the clinical situation.  
 
We suggest that the method described in this paper is a viable option to eliminate the 
complications of interpreting crossmatch results in those patients who have received 
rituximab therapy. This method may be modified for use of elimination of other 
interfering chimeric antibodies as many more of these products are being used clinically. 
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Figure 1.  Flow cytometric crossmatch histogram between donor spleen cells and 
normal human serum (in blue), normal human serum containing 10 µg /mL of 
rituximab (in green), and after 5 depletion treatments described herein (in orange), 
and a positive control containing alloantibody, but no rituximab (in red).  The 
presence of rituximab’s Fc portion gave a prominent positive peak comparable to 
alloantibody positive control (in red), a result of the recognition of FITC labeled anti-
human IgG1. The reduced rituximab in the adsorbed serum was indicated by a 
smaller number of fluorescence labeled cells, recognized by FITC labeled anti-human 
IgG1. The peak positive channel shifted to the left of the histogram, and the intensity 
decreased indicating that after adsorption, less rituximab was bound to the cells to be 
identified by binding of the goat anti-human IgG F(ab’)2 FITC conjugated antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2. Flow cytometric cross match histogram between donor spleen cells and normal 
human serum containing no rituximab (in red), normal human serum containing 10 µg 
/mL of rituximab (in green), and normal human serum containing 10 µg /mL of rituximab 
after 5 depletion treatments described herein (in orange), and a positive control 
containing alloantibody, but no rituximab (in blue). The fluorescent antibody used was 
phycoerytherin (PE) labeled anti-human CD20.  In the absence of rituximab to compete 
with fluorescence anti-CD20, a positive binding of PE labeled anti-CD20 was detected in 
the donor cells, indicated by the positive peak in the histogram. The reduced peak with 
serum containing rituximab showed blocking of the CD20 antigen by rituximab. After 5 
depletion treatments, reduced rituximab in the serum was indicated by a positive binding 
of PE labeled anti-CD20 comparable to the normal human serum.fluorescence labeled 
cells detected by PE anti-human CD20. The CD20 antigen detection was not effected by 
positive alloantibody. 
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